<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22180432</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>09</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1592-8721</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>97</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Haematologica</Title>
                <ISOAbbreviation>Haematologica</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>771-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2011.049155</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited. BL22 is a recombinant protein composed of the variable region of a monoclonal antibody that binds to CD22 and of PE38, a truncated Pseudomonas exotoxin. BL22 is a very potent drug already used in patients with hairy cell leukemia, whereas in chronic lymphocytic leukemia its cytotoxicity is limited by a lower expression of CD22. Here we demonstrate that this limitation can be overcome by pre-activation of chronic lymphocytic leukemia cells with bryostatin 1.</AbstractText>
                <AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">Primary malignant B cells from chronic lymphocytic leukemia and mantle cell lymphoma patients were used in vitro to assess the therapeutic impact of drug combinations using BL22 and bryostatin 1.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrate that bryostatin 1 sensitizes chronic lymphocytic leukemia cells for the cytotoxic effects of BL22 through activation of protein kinase C and subsequently increased CD22 surface expression. Dose and time response analysis reveals that activation of protein kinase C further activates an autocrine feedback loop degrading protein kinase C-βII protein. Depletion of protein kinase C-βII and upregulation of CD22 persist for several days following pre-stimulation with bryostatin 1. Therefore, our data provide a rationale for the sequential administration of BL22 following bryostatin 1 treatment. In addition to primary chronic lymphocytic leukemia cells, bryostatin 1 also sensitizes diffuse large B-cell lymphoma and mantle cell lymphoma cells to BL22 induced apoptosis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data suggest that the combination of bryostatin 1 with antibodies directed against CD22 is a potent drug combination for the treatment of low- and high-grade B-cell lymphoma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Biberacher</LastName>
                    <ForeName>Viola</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine III, Hematology and Oncology, Technical University, Munich, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Decker</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oelsner</LastName>
                    <ForeName>Madlen</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wagner</LastName>
                    <ForeName>Michaela</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bogner</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidt</LastName>
                    <ForeName>Burkhard</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kreitman</LastName>
                    <ForeName>Robert J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peschel</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pastan</LastName>
                    <ForeName>Ira</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meyer Zum Büschenfelde</LastName>
                    <ForeName>Christian</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ringshausen</LastName>
                    <ForeName>Ingo</ForeName>
                    <Initials>I</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>Haematologica</MedlineTA>
            <NlmUniqueID>0417435</NlmUniqueID>
            <ISSNLinking>0390-6078</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D054713">Bryostatins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004768">Enterotoxins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000922">Immunotoxins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C431326">RFB4(dsFv)-PE38 recombinant immunotoxin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051918">Sialic Acid Binding Ig-like Lectin 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>37O2X55Y9E</RegistryNumber>
                <NameOfSubstance UI="C046785">bryostatin 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.13</RegistryNumber>
                <NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.13</RegistryNumber>
                <NameOfSubstance UI="D064546">Protein Kinase C beta</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054713" MajorTopicYN="N">Bryostatins</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004768" MajorTopicYN="N">Enterotoxins</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000922" MajorTopicYN="N">Immunotoxins</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015451" MajorTopicYN="N">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016393" MajorTopicYN="N">Lymphoma, B-Cell</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020522" MajorTopicYN="N">Lymphoma, Mantle-Cell</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064546" MajorTopicYN="N">Protein Kinase C beta</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051918" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 2</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22180432</ArticleId>
            <ArticleId IdType="pii">haematol.2011.049155</ArticleId>
            <ArticleId IdType="doi">10.3324/haematol.2011.049155</ArticleId>
            <ArticleId IdType="pmc">PMC3342982</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Mar;6(3):825-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10741703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Haematol. 1998 Sep;102(5):1323-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9753063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2000 Aug 31;19(37):4263-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10980600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem. 2000 Aug;8(8):1841-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11003129</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2001 Apr 15;19(8):2165-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11304768</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2001 Jul 26;345(4):241-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11474661</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 2001 Nov 30;276(48):44944-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11581255</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 2003 Apr;30(2):253-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12720147</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Bioorg Med Chem Lett. 2003 Jun 2;13(11):1857-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12749884</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2003 Aug 15;21(16):3051-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12837807</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Invest. 2003;21(6):924-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14735696</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2004 Apr 1;103(7):2718-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14525789</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 2004 Aug;18(8):1391-400</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15175625</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leuk Lymphoma. 2004 May;45(5):997-1008</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15291360</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1984 Jan;63(1):140-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6418229</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1990 Feb 1;75(3):709-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2297573</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 1990 Mar 21;82(6):501-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2313723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Hematol. 1992 Aug;40(4):264-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1354412</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Hematol. 1993 Jan;21(1):61-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8093352</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Soc Trans. 1995 Feb;23(1):153-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7758717</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 1997 Jan;11(1):64-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9001420</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 1997 Mar;51(3):439-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9058599</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 1997 May 1;89(9):3378-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9129045</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Annu Rev Immunol. 1997;15:481-504</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9143697</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Haematol. 1999 Sep;106(4):995-1004</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10520003</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Jun 20;23(18):4079-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15767648</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2005 Sep 20;23(27):6719-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16061911</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hematology Am Soc Hematol Educ Program. 2005;:285-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16304393</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Aug 20;24(24):3880-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16864854</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Oct 1;12(19):5809-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17020988</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2007 Feb 1;109(3):1193-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17003377</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2009 Mar 19;113(12):2791-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19168795</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2009 Sep;64(4):803-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19221754</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Sep 20;27(27):4578-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19704063</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 2010 Jan;24(1):141-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19907441</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Haematol. 2010 Jan;148(1):99-109</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19821820</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Apr 1;28(10):1749-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20194866</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2010 Jul;30(14):3444-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20457813</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Jan;16(1):56-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9440723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 1998 Mar;4(3):611-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9533528</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Apr;6(4):1476-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10778980</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>